Cynosure Group LLC Has $360,000 Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Cynosure Group LLC reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 19.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,426 shares of the company’s stock after selling 1,850 shares during the period. Cynosure Group LLC’s holdings in Amphastar Pharmaceuticals were worth $360,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMPH. CANADA LIFE ASSURANCE Co raised its holdings in shares of Amphastar Pharmaceuticals by 29.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 39,930 shares of the company’s stock worth $1,752,000 after buying an additional 9,037 shares in the last quarter. Hancock Whitney Corp boosted its stake in shares of Amphastar Pharmaceuticals by 58.4% in the 1st quarter. Hancock Whitney Corp now owns 6,107 shares of the company’s stock valued at $268,000 after purchasing an additional 2,252 shares in the last quarter. Invst LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 1st quarter valued at approximately $251,000. Mendota Financial Group LLC acquired a new position in Amphastar Pharmaceuticals during the 2nd quarter worth approximately $180,000. Finally, Assenagon Asset Management S.A. lifted its stake in Amphastar Pharmaceuticals by 22.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 189,605 shares of the company’s stock valued at $7,584,000 after purchasing an additional 35,306 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, Director Richard K. Prins sold 5,000 shares of the stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the sale, the director now directly owns 31,471 shares in the company, valued at $1,535,784.80. This represents a 13.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the transaction, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at $3,900,522.90. This represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 27,533 shares of company stock worth $1,378,252. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock opened at $45.21 on Friday. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of 15.07, a P/E/G ratio of 0.89 and a beta of 0.82. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92. The company’s fifty day moving average is $47.91 and its 200 day moving average is $44.51.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $60.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.